InMed Pharmaceuticals Inc. (INM) Q2 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. My name is Shannon, and I will be your conference operator today. At this time, I would like to welcome everyone to NMED's second quarter fiscal 2022 financial results and business update conference call for the period ended December 31st, 2021. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star, then the number one on your telephone keypad. If you would like to withdraw your question, press the pound key. Thank you. Mr. Clancy, you may begin your conference. Thank you, Shannon, and good day, ladies and gentlemen. My name is Colin Clancy, INMED Senior Director of Investor Relations. Welcome to INMED's second quarter fiscal 2022 financial results and business update conference call. Please note our speakers are joining today from remote locations, so we appreciate your patience if we encounter any unexpected technical challenges. Before we begin, we'd like to go over our disclosure statements. followed by an update on our health and wellness commercial activities, together with a progress update on our pharmaceutical drug development programs, which will be led by our President and CEO, Eric Adams. Mr. Bruce Caldwell, our Chief Financial Officer, will then review the financial results of operations. Following that, we will be available for questions and answer sessions. Also joining us today to address your questions will be Eric Hsu, Senior Vice President of Preclinical Research and Development, Alexandra Mancini, Senior Vice President, Clinical and Regulatory Affairs, Shane Johnson, Senior Vice President and General Manager of BayMedica, and Michael Woodenberg, Vice President of Chemistry, Ma...